Brief: UBS Group's Long Position In H Shares Of Shanghai Henlius Biotech Increases To 7.55% - HKEX
19/02/2025 11:42
Feb 19 (Reuters) - HKEX:
* UBS GROUP'S LONG POSITION IN H SHARES OF SHANGHAI HENLIUS
BIOTECH 2696.HK INCREASES TO 7.55% ON FEB 13 FROM 5.43% - HKEX
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln